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Objective
To better risk stratify patients, using baseline characteristics, to
help optimise decision-making for men with moderate-to-
severe lower urinary tract symptoms (LUTS) secondary to
benign prostatic hyperplasia (BPH) through a secondary
analysis of the Medical Therapy of Prostatic Symptoms
(MTOPS) trial.
Patients and Methods
After review of the literature, we identiﬁed potential baseline
risk factors for BPH progression. Using bivariate tests in a
secondary analysis of MTOPS data, we determined which
variables retained prognostic signiﬁcance.We then used these
factors in Cox proportional hazard modelling to: i) more
comprehensively risk stratify the study population based on
pre-treatment parameters and ii) to determine which risk
strata stood to beneﬁt most from medical intervention.
Results
In all, 3047 men were followed in MTOPS for a mean of
4.5 years. We found varying risks of progression across
quartiles. Baseline BPH Impact Index score, post-void
residual urine volume, serum prostate-speciﬁc antigen (PSA)
level, age, American Urological Association Symptom Index
score, and maximum urinary ﬂow rate were found to
signiﬁcantly correlate with overall BPH progression in
multivariable analysis.
Conclusions
Using baseline factors permits estimation of individual
patient risk for clinical progression and the beneﬁts of
medical therapy. A novel clinical decision tool based on
these analyses will allow clinicians to weigh patient-speciﬁc
beneﬁts against possible risks of adverse eﬀects for a given
patient.
Keywords
benign prostatic hyperplasia (BPH), lower urinary tract
symptoms (LUTS), risk factors
Introduction
BPH can progress over time. Community based studies have
estimated that >30% of men will experience clinical
progression in the course of 5 years [1–4], predominantly
characterised by increases in LUTS severity [5,6].While BPH
is highly prevalent, not all men with BPH have the same risk
for progression [7,8].
Determining predictors of this risk has been an ongoing
process over the past decade. A few trials have examined
their placebo arms to elucidate baseline characteristics that
portend worse prognoses [9,10]. However, these eﬀorts have
generally focused on a single factor, such as initiation of
5α-reductase inhibitors (5-ARIs), for men with enlarged
prostates or elevated PSA levels. In clinical practice, this may
translate into focusing on an isolated variable to risk stratify
when patients have multiple factors that might
simultaneously inﬂuence the risk of progression and the
potential beneﬁts of therapy.
With the combined use of α-blockers and 5-ARIs, men can
reduce their risk of BPH progression and ultimate need for
invasive procedures. The Medical Therapy of Prostatic
Symptoms (MTOPS) trial demonstrated clear beneﬁt in risk
reduction with this medical combination [6]. Classically,
clinical trials showing a positive result suggest that
practitioners should adopt a ‘treat all’ strategy. Yet, just as
patient risk of progression can be variable, a given patient’s
response to medical therapy may diverge from the mean, a
concept known as heterogeneity of treatment eﬀect.
It has recently been proposed that the results of clinical trials
be routinely analysed and presented in a risk-stratiﬁed fashion
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to examine the relative and absolute eﬀects across diﬀerent
risk strata, as baseline risk is a mathematical determinant of
the treatment eﬀect and can diﬀer greatly across patients in a
trial [11–13]. To date, it remains unknown how the beneﬁts of
available therapies for BPH vary across patients at diﬀerent
progression risks, and such information could have important
implications for clinical practice.
To better aid clinicians with decision making, we sought to
risk stratify men with moderate-to-severe LUTS secondary to
BPH using established risk factors in a data-driven model.
With data from the MTOPS, we examined trial outcomes
across risk strata of BPH progression to better deﬁne which
patients are most likely to beneﬁt from α-blockers, 5-ARIs, or
their combination.
Patients and Methods
We obtained original, publicly available data from the MTOPS
study. The MTOPS study was conducted by the MTOPS
Investigators and supported by the National Institute of
Diabetes and Digestive and Kidney Diseases (NIDDK).
Approval for our present analysis was provided by NIDDK
and the study was approved by the Tufts Medical Center
Internal Review Board [14]. The design, rationale, and
outcomes of the MTOPS study are described in detail
elsewhere [6]. In short, MTOPS was a randomised trial
evaluating doxazosin, ﬁnasteride, or the combination of these
medications for risk of BPH progression in men aged ≥50
years with AUA Symptom Index (AUA-SI) scores of 8–30 and
maximum urinary ﬂow rates (Qmax) of 4–15 mL/s enrolled
between 1993 and 1998. BPH progression, or the primary
outcome, was deﬁned as ‘the ﬁrst occurrence of an increase
over base line of at least four points in the AUA-SI score, acute
urinary retention, renal insuﬃciency, recurrent urinary tract
infection, or urinary incontinence’ [6].
To capture potential variables for risk stratiﬁcation, we
reviewed the current literature. Within their primary
analysis, MTOPS investigators found that baseline PSA level
and baseline prostate volume signiﬁcantly correlated with
progression in univariate analysis [6]. We identiﬁed two
other models predictive of BPH progression based on: i)
randomised-controlled trials with a diﬀerent 5-ARI
(dutasteride) [8,15] and ii) expert consensus [16]. These
revealed additional potential risk factors: age, severe
symptoms (as deﬁned by both the BPH Impact Index (BII)
[17] and the AUA-SI [18]; Appendix 1), lower Qmax, and
elevated post-void residual urine volume (PVR). Review of
other community based surveys and placebo-controlled trials
further supported the relevance of these variables
[1,2,19–23].
Using Cox proportional hazards regression, we conducted
univariate tests to determine which of these variables,
measured at baseline, were associated with the outcome.We
then used the factors with P-values <0.1 in a multivariate Cox
model, excluding treatment assignment. As the GP does not
typically assess PVR or Qmax in a primary care setting, we
attempted to make our work more broadly applicable by
creating a reduced model with easily measured factors (age,
PSA level, AUA-SI, BII). The full and reduced Cox models
were internally validated with bootstrapping to quantify
optimism in model performance.We evaluated model
performance with the c-statistic [24]. Calibration
was evaluated with a calibration plot and modiﬁed
Hosmer–Lemeshow chi-squared test for survival analysis
[25] and was excellent (chi-squared P = 0.99).
From both the full and reduced Cox regression models, in
separate analyses, we stratiﬁed the trial population into
equal-sized risk quartiles.Within each risk quartile, we
calculated the active drug treatment eﬀect compared with
placebo for each of the three intervention arms (i.e.,
doxazosin, ﬁnasteride, combination). Using Kaplan–Meier
estimated failure rates after 4 years of follow-up, we calculated
the absolute risk reduction and number needed to treat for
each drug or drug combination compared with placebo, as
well as the combined therapy compared with each active drug
individually. Heterogeneity of treatment eﬀect was assessed by
including an interaction term in the Cox regression model
between the baseline linear risk predictor and treatment
assignment to estimate the eﬀect of treatment as a function
of risk in BPH progression.
Finally, with results from the internally validated models, we
constructed a clinical decision tool (nomogram) for care
providers. Data management and regression model building
were performed using SAS version 9.3 (SAS Institute, Cary
NC).We used Frank Harrell’s ‘rms’ package in R software
version 3.0.1 to perform the bootstrapped internal validation
and generate the nomogram.
Results
In all, 3047 men were followed in MTOPS for a mean of
4.5 years. They were randomised to four arms: placebo (737
men), doxazosin (756), ﬁnasteride (768), and combined
therapy (786). In all, 351 primary outcome events (i.e., BPH
progression events) occurred in total, with 128 in the placebo
arm, 85 in the doxazosin arm, 89 in the ﬁnasteride arm,
and 49 in the combination arm. These were predominantly
characterised as increases in symptom severity (78%), but did
include acute urinary retention (12%), incontinence (9%), and
recurrent UTI/urosepsis in ﬁve cases. The 4-year overall risk
of clinical progression within the placebo arm was 17%,
compared with 10% in the doxazosin arm, 10% in ﬁnasteride
arm, and 5% in combined therapy arm (all previously reported
P-values <0.002) [6]. Baseline characteristics of the study
patients are shown in Table 1. Because collection of the
variables of interest was excellent, we used complete case
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analysis and excluded only nine subjects from the full
multivariate model and four from the reduced multivariate
model.
Bivariate analysis was performed on all clinically relevant
variables based on our literature review (Table 2). Variables
showing statistical signiﬁcance were then used to create a
parsimonious, multivariable model of BPH progression risk.
Baseline BII score (per 1 point, hazard ratio [HR] 1.12, 95% CI
1.07–1.17), PVR (per 100 mL, HR 1.17, 95% CI 1.04–1.30),
serum PSA level (per 5 ng/mL, HR 1.44, 95% CI 1.14–1.82),
age (per 10 years, HR 1.33, 95% CI 1.15–1.53), AUA-SI score
(per 5 points, HR 0.76, 95% CI 0.68–0.85), and Qmax (per
5 mL/s, HR 0.74, 95% CI 0.60–0.90) were found to be
signiﬁcantly negatively correlated with overall BPH
progression in multivariable analysis (Table 3). Internal
Table 1 Baseline characteristics of MTOPS cohort.
Characteristic Cohort Placebo Doxazosin Finasteride Combined therapy
Number of patients 3047 737 756 768 786
Mean (SD)
Age, years (range 50–89) 62.6 (7.3) 62.5 (7.6) 62.7 (7.3) 62.6 (7.3) 62.7 (7.1)
AUA-SI score (range 8–35) 16.9 (5.9) 16.8 (6.0) 17 (5.9) 17.1 (6.0) 16.8 (5.8)
Prostate volume, mL (range 6.1–185.0) 36.3 (20.1) 35.2 (18.9) 36.9 (21.6) 36.9 (20.6) 36.4 (19.2)
Qmax, mL/s (range 4–15.3) 10.5 (2.6) 10.5 (2.7) 10.3 (2.6) 10.5 (2.6) 10.6 (2.5)
PVR, mL (range 0–789) 68.1 (82.9) 69.6 (82.1) 69.2 (88.3) 66.2 (80.1) 67.5 (81.2)
Serum PSA level, ng/mL (range 0.2–10.5) 2.4 (2.1) 2.3 (2.1) 2.4 (2.2) 2.4 (2.1) 2.3 (2.0)
Serum glucose level, ng/dL (range 6–465) 100.1 (42.5) 100.8 (43.9) 99.3 (41.6) 98.6 (37.4) 101.6 (46.4)
Body mass index, kg/m2 (range 16.5–52.1) 27.8 (4.2) 27.6 (4.0) 27.7 (3.9) 27.9 (4.6) 27.9 (4.2)
BII score (range 0–13) 4.0 (2.7) 4.0 (2.7) 3.9 (2.7) 4.1 (2.8) 4.0 (2.7)
N (%)
Primary school education only 120 (3.9) 29 (3.9) 36 (4.8) 31 (4.0) 24 (3.1)
Family history of prostate cancer:
Yes 416 (13.7) 95 (12.9) 94 (12.4) 98 (12.8) 129 (16.4)
No 2228 (73.1) 545 (74.0) 546 (72.2) 578 (75.3) 559 (71.1)
Unknown 403 (13.2) 97 (13.2) 116 (15.3) 92 (12.0) 98 (12.5)
Erectile dysfunction:
Yes 747 (24.6) 185 (25.1) 196 (26.0) 184 (24.0) 182 (23.2)
No 1745 (57.4) 417 (56.7) 423 (56.0) 456 (59.4) 449 (57.3)
Intermittent 550 (18.1) 134 (18.2) 136 (18.0) 128 (16.7) 152 (19.4)
History of diabetes 260 (8.5) 72 (9.8) 59 (7.8) 65 (8.5) 64 (8.1)
History of hypertension 871 (28.6) 203 (27.5) 226 (29.9) 212 (27.6) 230 (29.3)
HR (95% CI) for the treatment arms were as follows: doxazosin 0.54 (0.40–0.72), ﬁnasteride 0.60 (0.45–0.80), combination 0.27 (0.19–0.39).
Table 2 Bivariate analysis: baseline characteristics and their correlation with risk of BPH progression.
Characteristics identified within our literature search, as well as a number of other factors collected
within MTOPS data were analysed.Variables are plotted with their model coefficients and HRs.
Standard errors are noted for each estimate.
Variable Estimate SE P HR
Age, year 0.037 0.007 <0.001 1.038
AUA-SI score –0.024 0.009 0.010 0.976
Prostate volume, mL 0.010 0.002 <0.001 1.010
Qmax, mL/s –0.059 0.020 0.004 0.943
PVR, mL 0.002 0.001 0.001 1.002
Serum PSA level, ng/mL 0.110 0.022 <.001 1.116
BII score 0.045 0.019 0.018 1.046
Serum glucose, ng/dL –0.001 0.001 0.713 1.000
Body mass index, kg/m2 –0.002 0.013 0.893 0.998
Primary school education only, yes vs no 0.351 0.242 0.147 1.421
Family history of prostate cancer
Yes –0.076 0.160 0.636 0.927
No 1.00 (reference)
Unknown 0.204 0.148 0.168 1.226
Erectile dysfunction
Yes 0.212 0.119 0.076 1.236
No 1.00 (reference)
Intermittent 0.007 0.137 0.958 1.007
History of diabetes, yes vs no 0.083 0.185 0.656 1.086
History of hypertension, yes vs no 0.017 0.119 0.884 1.017
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validation after 500 bootstrap repetitions revealed an
optimism-corrected c-statistic of 0.626 compared with 0.635
in the original dataset.
This predictive model of risk for BPH progression (c-statistic
= 0.635) showed varying risks of progression across quartiles
(Fig. 1). Formal tests of interaction between risk and treatment
were not signiﬁcant (data not shown), indicating that patients
experienced roughly proportional beneﬁts across risk strata
from the three diﬀerent treatments. However, the highest-risk
quartile had a risk of progression ≈300% that of the lowest
within all trial arms on the absolute risk reduction scale. Thus,
the number needed to treat for those patients in the lowest
quartile of risk was about three-times that for patients in the
highest quartile. MTOPS showed a 17% overall incidence of
clinical progression for the ‘average’ patient [6], but a patient
within the lowest quartile only bears a progression risk of
10.7%, while the typical highest quartile patient faces up to
a 29.6% risk of progression. To facilitate a more direct
comparison between serious adverse events (SAEs) and
therapeutic beneﬁts, we stratiﬁed those SAEs that resulted in
medication interruption or discontinuation that occurred
before a primary outcome event within the ﬁrst 4 years of
follow-up (Fig. 2). This ﬁgure shows a clear increase in the
ratio of the beneﬁts to the side-eﬀects of therapy as risk
increases.
Our reduced model retained predictive value with a c-statistic
of 0.623 (Table 4), compared with 0.635 with the full model
(Table 3). This suggests that these easily attainable parameters
can be used in various clinical settings to predict risk of BPH
progression. Clinical decision tools were then constructed
from these models (Appendix 2 and Fig. 3).
Discussion
While MTOPS reported an overall incidence of clinical
progression of 17% in the placebo group, we showed that this
risk is variable among men.Whereas beneﬁts of medical
therapy for patients with a high risk of progression are clear,
the beneﬁts to patients at lower risk are less so, and may be
more ﬁnely balanced with risks and sensitive to patient
preferences.
Prior studies have oﬀered several predictive baseline factors
for the clinical progression of BPH. These have included
increased symptom severity (both AUA-SI and BII), low Qmax,
high PVR, high prostate volume, and high serum PSA level
[8,9,19,20,26]. Age has also been reported to have prognostic
value [6]. Similar to these previous reports, we found several
predictive characteristics, including age, serum PSA level,
PVR, Qmax, BII score, and AUA-SI score.
Of note, the AUA-SI score has a HR <1 in our model,
indicating that higher symptoms are protective against
progression. This is probably because those men with severe
Table 3 Multivariable Cox proportional hazards model.Variables are listed
with their respective HRs. Prostate volume did not (by neither DRE nor TRUS
estimate) maintain significance in our multivariable model.
Variable HR 95% Wald CL
Age (per 10 years) 1.33 1.15, 1.53
Serum PSA (per 5 ng/mL) 1.44 1.14, 1.82
AUA-SI score (per 5 points) 0.76 0.68, 0.85
BII score (per 1 point) 1.12 1.07, 1.17
Qmax (per 5 mL/s) 0.74 0.60, 0.90
PVR (per 100 mL) 1.17 1.04, 1.30
N = 3036 with non-missing data for all predictors. CL, conﬁdence limit. c-statistic =
0.635.
***Event rates (%) are listed in the table below. 
Placebo
Doxazosin
Finasteride
Combination
Q1 Q2 Q3 Q4
10.7 12.8 18.9 29.6
5.2 7.8 11.3 16.6
5.8 9.3 13.8 15.9
1.8 3.1 6.8 9.7
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Quartiles (based on risk of BPH progression in MTOPS)
Fig. 1 The 4-year risk of BPH progression
stratified across quartiles. Linear predictor
scores from our full model were used to
generate a spectrum of risk, which we divided
into quartiles. This was performed for all four
arms of MTOPS. The observed mean event
rates for each arm within each quartile were
collected based on Kaplan–Meier estimated
event rates within the MTOPS trial.
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symptoms were less likely to progress to even worse
symptoms (as detected by the AUA-SI) during the follow-up
period.
In our ﬁnal model, prostate volume was not necessary to
yield optimal prognostic information.While seemingly in
contrast to prior studies [6,10,26,27], which suggested that
larger prostate volumes are associated with higher risk of
BPH progression, our multivariable analysis suggests
that once PSA level and symptom severity score are
included, the information gained from knowing prostate size
was no longer statistically signiﬁcant in predicting BPH
progression. This ﬁnding is particularly relevant in the
primary care setting, where the availability of prostate
ultrasound to measure size is uncommon. Of note, our
ﬁndings cannot be generalised to men outside the MTOPS
entry criteria.
Prior analyses [6,27,28] suggested that elevated serum PSA
level and higher total prostate volume were the strongest
predictors of BPH progression. The present analysis suggests
that focusing on these two factors in isolation would fail to
capture the entire clinical picture for a given patient. As one
can imagine, in patients who have conﬂicting characteristics,
decisions made on a single factor may inappropriately guide
therapy. Moreover, univariable analyses tend to highlight a
certain threshold (e.g., a patient’s prostate is considered
enlarged if it is >30 mL), but such decision points can
arbitrarily endorse treatment or no treatment again for the
non-ideal candidate.
Using our present derived nomogram will allow clinicians to
account for the key factors that have been shown to predict
disease progression in a large, prospective clinical trial. A
patient’s age, AUA-SI score, BII score, and serum PSA level can
easily be collected during a clinical encounter. These values
can then be translated into a ‘Total Points’ within our
nomogram, as described in Fig. 3, and ultimately into a risk of
progression. Clinicians can then weigh this risk of progression
against the potential risk of side-eﬀects, as brieﬂy outlined in
Fig. 2, and other patient-speciﬁc characteristics (e.g., patient
compliance, medication costs to the patient).We hope to
ultimately translate this nomogram into a user-friendly,
web-based application.
Other groups have created clinical tools in an eﬀort to help
physicians most eﬀectively employ medical therapy for BPH.
Lowe et al. [16] surveyed 12 international ‘experts’ on BPH
using over 240 hypothetical patient scenarios to determine the
NNT (vs placebo) Q1 Q2 Q3 Q4 
Doxazosin 19 20 14 7
Finasteride 21 30 20 8
Combination 12 11 9 6
vs doxazosin 30 22 23 15 
vs finasteride
ARR, absolute risk reduction compared to placebo; NNT, number needed to treat (1/ARR). 
25 17 15 17
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Absolute risk reduction (ARR) Serious Adverse Events (SAEs) Fig. 2 Medication treatment effects in terms of
absolute risk compared to SAEs that resulted in
therapy interruption/discontinuation. Absolute
risk reductions (with 95% CI) for the different
treatment arms are calculated compared with
the placebo arm and increase over quartiles
of BPH progression, ordered from left to right
(Q1–>Q4), with each treatment arm reported
(ordered as doxazosin (D), finasteride (F),
combination (C) in each quartile). SAEs (with
95% CI) are reported in raw percentages
(listed as negative values for comparison). The
number needed to treat (NNT) is derived from
the absolute risk reductions in the respective
groups, as listed in the table below.
Table 4 Reduced multivariable Cox proportional hazards model. This
model retains its predictive value over a similar range of decision
thresholds compared with the full model (Table 3). However, this model
includes variables that may be easily measured in primary care settings,
allowing for broader applicability.
Variable HR 95% Wald CL
Age (per 10 years) 1.35 1.17, 1.56
Serum PSA (per 5 ng/mL) 1.52 1.21, 1.91
AUA-SI score (per 5 points) 0.79 0.70, 0.88
BII score (per 1 point) 1.12 1.07, 1.17
N = 3043 with non-missing data for all predictors. CL, conﬁdence limit. c-statistic =
0.623.
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most important prognostic factors for progression. This panel
concluded that symptom severity, low Qmax, and elevated PVR
were the most important determinants for progression,
although PSA level and prostate volume were also considered
signiﬁcant. The authors formulated a regression model to
predict risk based on the panel’s responses.
Additionally, Slawin et al. [8,15] performed secondary analysis
on three 2-year, multicentre, placebo-controlled, double-blind
randomised trials with dutasteride to create a clinical
nomogram for the risk of acute urinary retention or
BPH-related surgery. However, those data were limited to men
with larger prostates (>30 mL) and had a shorter follow-up
time than MTOPS (2 years vs 4.5 years). Moreover, MTOPS
showed, in a more inclusive sample, that progression
predominantly manifests as worsening symptom severity as
opposed to retention or surgery. As such, the Slawin model
can assist in more specialised, second-line settings, while
our present model may be more widely applicable to the
treatment-naïve population. Additionally, while they examined
the variable risk of progression, ours remains the ﬁrst study to
examine combined medical therapy in a risk-stratiﬁed
analysis.
Clinical decisions must also consider the AEs of possible
interventions. For those men in MTOPS who received active
therapy, 27% stopped doxazosin, 24% stopped ﬁnasteride, and
18% stopped combined therapy. Medication cessation was
most often because of AEs [6].We found that the risk of
medication discontinuation was relatively stable across
quartiles of progression risk, at 8–15%. Clinicians can use our
present decision tool to weigh a patient’s risk of progression
against this risk of discontinuation to determine if there may
be a realised beneﬁt in initiating medical therapy.
As with most statistical models, our present ﬁndings may be
subject to over-ﬁtting and would beneﬁt from external
validation in another cohort. However, by basing our model
on just a handful of clinically relevant variables and by having
a large number of outcome events for each variable tested,
over-ﬁtting is less likely to have impacted our primary
conclusions, although miscalibration to the external
population could aﬀect the beneﬁts of using the model.
Additionally, for methodological reasons, we excluded therapy
from our model, which lowered the c-statistic; inclusion would
have greatly improved discrimination, as the medications
were so eﬀective. Furthermore, while we postulated that our
ﬁndings might improve eﬀectiveness of these pharmacological
interventions at the population level, no cost data were
collected in the MTOPS trial, so cost-eﬀectiveness analyses
were not performed here.
In conclusion, the risk of BPH progression is highly variable
among men. MTOPS data suggests that the beneﬁts of medical
therapy for BPH are unevenly distributed with men who were
in the highest risk strata accounting for the greatest clinical
if total points =
then risk quartile =
Q1 Q2 Q3 Q4 
4-year rate of progression without treatment
To calculate event rate with therapy, multiple by 
treatment hazard ratio (95% confidence interval) 
Doxazosin Finasteride Combination
0.54 (0.40, 0.72) 0.60 (0.45, 0.80)
<116 116–136 136–156 >156
14.9% 10.6% 14.4% 31.7% 
0.27 (0.19, 0.39)
Points
Age, years
AUA Symptom Score
BPH Impact Index
PSA, ng/mL
0 10 20 30 40 50 60 70 80 90 100
50 55 60 65 70 75 80 85 90
36 34 32 30 28 26 24 22 20 18 16 14 12 10 8
0 1 2 3 4 5 6 7 8 9 10 11 12 13
0 2 4 6 8 10 12
Fig. 3 Reduced model. Clinical decision tool
for predicting 4-year risk of clinical BPH
progression using data from MTOPS, four
predictor regression model. To determine an
individual's risk of progression, draw a vertical
line from each of the patient's factors to the
‘Points’ line above. Add the four ‘Points’ values
together to arrive at a ‘Total Points’. Calculate
the expected event rate with therapy by
applying the HRs below.
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beneﬁt. Importantly, using commonly available baseline risk
factors permits estimation of the patient-speciﬁc risk for
clinical progression, and thus the potential for beneﬁt. Our
present novel decision tool based on clinically available factors
(age, AUA-SI score, BII score, serum PSA level) may allow
clinicians to better select those most likely to beneﬁt from
medical therapy for BPH and potentially inform future
guidelines. Potential treatment eﬀect can then be weighed
against possible risks of AEs for a given patient.
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Appendix 1
Impact and symptom indices for BPH (adapted from Barry MJ. Evaluation of symptoms and quality of life in men with benign
prostatic hyperplasia. Urology 2001; 58 (Suppl. 1): 25–32.)
Benign Prostatic Hyperplasia Impact Index (BPH-II)
None Only a little Some A lot
1. Over the past month, how much physical discomfort did any urinary problems cause you? 0 1 2 3
2. Over the past month, how much did you worry about your health because of any urinary
problems?
0 1 2 3
Not at all
bothersome
Bothers
me a little
Bothers
me some
Bothers
me a lot
3. Overall, how bothersome has any trouble with urination been during the past month? 0 1 2 3
None of
the time
A little of
the time
Some of
the time
Most of
the time
All of
the time
4. Over the past month, how much of the time has any urinary problem kept you from doing
the kind of things you would usually do?
0 1 2 3 4
Total Score: _______________
Baseline characteristics predict BPH progression
© 2014 The Authors
BJU International © 2014 BJU International 315
Appendix 2
Full Model – Clinical decision tool for predicting 4-year risk of clinical BPH progression using data from MTOPS. In order to
determine an individual’s risk of progression, draw a vertical line from each of the patient’s factors to the ‘Points’ line above.
Add the six ‘Points’ values together to arrive at a ‘Total Points’. Calculate the expected event rate with therapy by applying the
hazard ratios below.
if total points =
then risk quartile =
4-year rate of progression without treatment
< 143 143–158 158–181 >181
Q1 Q2 Q3 Q4 
10.70% 12.80% 18.90% 29.60%
To calculate event rate with therapy, multiple by
treatment hazard ratio (95% confidence interval)
Doxazosin Finasteride Combination
0.54 (0.40, 0.72) 0.60 (0.45, 0.80) 0.27 (0.19, 0.39)
Points
Age, years
AUA Symptom Score
BPH Impact Index
PVR, mL
Qmax, mL/s
PSA, ng/mL
0 10 20 30 40 50 60 70 80 90 100
50 55 60 65 70 75 80 85 90
36 34 32 30 28 26 24 22 20 18 16 14 12 10 8
0 1 2 5 6 7 8 9 10 11 12 13
0 100 200 300 400 500 600 700 800
16 14 12 10 4
3 4
8 6
0 2 4 6 8 10 12
if total points =
<143 143–158 158–181 >181
then risk quartile =
Q1 Q2 Q3 Q4
4-year rate of progression without treatment
10.70% 12.80% 18.90% 29.60%
To calculate event rate with therapy, multiple by treatment hazard ratio (95% confidence interval)
Doxazosin Finasteride Combination
0.54 (0.40, 0.72) 0.60 (0.45, 0.80) 0.27 (0.19, 0.39)
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